Page last updated: 2024-11-02

pioglitazone and Atherosclerotic Parkinsonism

pioglitazone has been researched along with Atherosclerotic Parkinsonism in 2 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bonato, JM1
Bassani, TB1
Milani, H1
Vital, MABF1
de Oliveira, RMW1
Ulusoy, GK1
Celik, T1
Kayir, H1
Gürsoy, M1
Isik, AT1
Uzbay, TI1

Other Studies

2 other studies available for pioglitazone and Atherosclerotic Parkinsonism

ArticleYear
Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats.
    Experimental neurology, 2018, Volume: 300

    Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Male; Mortality; Ne

2018
Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease.
    Brain research bulletin, 2011, Jul-15, Volume: 85, Issue:6

    Topics: Animals; Antineoplastic Agents; Antioxidants; Disease Models, Animal; Hypoglycemic Agents; Male; Mot

2011